Psychiatry AtlasMedication guide · United States

Antipsychotic medicine

Lurasidone (Latuda)

Generic name
lurasidone hydrochloride
Brand names
Latuda
Medication class
Antipsychotic medicine
Forms covered
oral tablets

Article updated: 2026-10-24 · Sources last checked: 2026-11-05

Medication Safety Alerts

Look-alike / sound-alike name

  • Latuda can be confused with Lantus.

FDA Boxed Warning

oral tablets.

Latuda carries warnings about increased mortality in older adults with dementia-related psychosis, for which it is not approved, and suicidal thoughts or behaviors in pediatric and young adult patients taking antidepressants. Monitor for worsening mood and suicidal thinking.

Lurasidone (Latuda) treats schizophrenia and bipolar I depression. It is not established as a treatment for mania, and every dose needs food.

What to expect: Full benefit can take several weeks or longer.

Warning signs
Sources last checked:
2026-11-05

What is this medicine used for?

FDA-approved uses

  • Schizophrenia — Adults and adolescents aged 13–17. Treatment of schizophrenia, with ongoing assessment of benefit and adverse effects.oral tablets.
  • Bipolar I depression as monotherapy — Adults and children/adolescents aged 10–17. Treatment of major depressive episodes associated with bipolar I disorder; not an established treatment for mania.oral tablets.
  • Bipolar I depression with lithium or valproate — Adults. Adjunctive treatment; this combination indication is not established for pediatric patients.oral tablets.

What should I expect?

Full benefit can take several weeks or longer. Look for improvement in depressive or schizophrenia symptoms, depending on the purpose of treatment, and tell the prescriber about troublesome restlessness or sleepiness.

Agree on a follow-up plan when treatment starts. Contact the prescriber if symptoms worsen, side effects disrupt daily life, or there is no useful improvement by the planned review; do not change the dose yourself.

How do I take it safely?

Take once daily with at least 350 calories of food. Do not take an extra dose to make up for taking one without food; ask the pharmacist. Kidney or liver problems and some interactions require a different prescribing plan.

Keep checks of weight, blood sugar, blood fats, blood pressure, movements, and mood. A history of low white-cell counts can require blood-count monitoring. Avoid driving until you know how it affects you.

Do not use after hypersensitivity to lurasidone or an ingredient. Do not combine with strong CYP3A4 inhibitors or strong CYP3A4 inducers.

Strong CYP3A4 inhibitors such as clarithromycin, ketoconazole or ritonavir, and strong inducers such as carbamazepine, phenytoin, rifampin or St John’s wort, are contraindicated with Latuda. Moderate inhibitors such as diltiazem or fluconazole require prescriber adjustment. Avoid grapefruit and grapefruit juice because they can alter exposure. Alcohol and sedating drugs may add to impairment. Lithium or valproate combinations still need their own safety and monitoring review, even though the label reports little pharmacokinetic interaction.

Available pregnancy data are limited and cannot establish the medication’s risk with confidence. Third-trimester antipsychotic exposure can cause newborn movement or withdrawal symptoms. The label reports inadequate human lactation-study information, so breastfeeding needs an individualized discussion. Pediatric indications begin at 13 for schizophrenia and 10 for bipolar depression monotherapy. Effectiveness for autism-related irritability is not established. Older adults require attention to kidney function, blood pressure, falls and the dementia-related boxed warning.

Take a missed dose when remembered unless the next dose is close, following the supplied patient instructions; do not double a dose. The meal requirement still matters. Discuss discontinuation with the prescriber because symptoms can return and a planned change may be needed. If several doses were missed or a new interacting medicine was started, obtain product-specific advice instead of using the previous dose automatically.

What side effects should I know about?

  • Restlessness or akathisia (feeling unable to keep still), stiffness or tremor, nausea and sleepiness.
  • Weight, blood sugar, lipid or prolactin changes may require clinical checks even without obvious symptoms.

Tell your prescriber about effects that are persistent, troublesome, or interfere with daily life.

Which warning signs need help?

  • Severe restlessness, new involuntary movements, fainting or signs of dangerous high blood sugar need prompt assessment.
  • New or worsening suicidal thoughts or severe mood changes require prompt help; immediate danger needs emergency care.
  • Seek emergency care for high fever with severe stiffness or confusion, trouble breathing, collapse, a seizure, or a suspected overdose. New involuntary movements, severe restlessness, or symptoms of high blood sugar need prompt medical assessment.

What else should I know to stay safe?

  • Do not use after allergy to lurasidone or its ingredients, or with strong medicines that alter the liver enzyme CYP3A4. Examples include clarithromycin, ketoconazole, ritonavir, carbamazepine, phenytoin, rifampin, and St John’s wort. Avoid grapefruit; other interacting drugs and kidney or liver impairment can require a different prescribing plan.
  • Keep checks of weight, blood sugar, blood fats, blood pressure, movements, and mood. Low white-cell counts can require blood-count monitoring. Alcohol and sedatives can worsen impairment. Lithium or valproate combinations still need their own safety checks; treatment changes and interruptions need prescriber advice.
  • Discuss pregnancy and breastfeeding because human evidence is limited. Later-pregnancy antipsychotic exposure can cause newborn movement or withdrawal problems. Older adults need particular attention to kidney function, low blood pressure, and falls.

Urgent help and crisis support · Emergency & Crisis Resources (US)

What can help day to day?

  • The food requirement is part of getting the intended amount of medicine into your body. A drink or a small snack may not provide the required 350 calories.
  • Bipolar depression and mania are different treatment targets. An approval for one does not establish effectiveness for the other.

How does it work?

Lurasidone changes responses to dopamine and serotonin, chemical messengers used by brain cells. It blocks some receptors, the proteins that receive these messages, and partly activates another type. These actions may contribute to its benefits, but the full explanation of how symptoms improve remains uncertain.

Explore medication science

How was this medicine developed?

The FDA first approved Latuda for schizophrenia in 2010. Later approvals added bipolar I depression and specified younger age groups. The food requirement remains a distinctive practical part of using it.

How do I say the name?

Lurasidone: loo-RAS-ih-dohn. Capital letters show the stressed syllable.

Sources and References

Sources support the U.S. products described here. Product instructions can differ; use the information supplied with your own medicine.

  1. Latuda: current US prescribing information (1/2025)
  2. MedlinePlus: lurasidone
  3. Drugs@FDA: Latuda approval and regulatory history
  4. Lurasidone Tablets: Package Insert / Prescribing Info / MOA
  5. DailyMed - LURASIDONE HYDROCHLORIDE tablet, film coated
  6. What Is a Neurotransmitter?
  7. FDA: Seroquel immediate-release label and Medication Guide
  8. FDA: lithium carbonate prescribing information and Medication Guide
  9. ISMP List of Confused Drug Names
  10. Latuda FDA prescribing information (January 2025)
  11. Frequently Asked Questions about Labeling for Prescription Medicines | FDA
  12. A qualitative investigation into the effects of akathisia - Health Research Authority
  13. Extrapyramidal side effects- Management
  14. Anxiety and panic attacks - NHS
  15. Agitation: MedlinePlus Medical Encyclopedia

Giving medicine safely to children: family guide (PDF, 3 pages)

How information is checked

Was this article helpful?

Was this article helpful?

Sends your choice, article identifier, edition and optional issue to Psychiatry Atlas. No name, email or medical details are requested. Daily network codes help prevent spam; hosting may process technical information. This is not a promise of anonymity. Privacy details.

Enable JavaScript to send feedback.

Suggest a missing topic or describe a correction. Please keep personal medical information out of website feedback.

Back to top